#1Commercial execution / Innovation and therapeutic focus Diabetes care CMD22 CAPITAL MARKETS DAY 3 MARCH H Camilla Sylvest EVP Commercial Strategy and Corporate Affairs Mike Doustdar EVP International Operations Doug Langa EVP North America Operations Martin Holst Lange EVP Development novo nordisk SIMONE LENSBØLE Simone lives with type 2 diabetes Denmark#22 Commercial execution and innovation Diabetes care Novo NordiskⓇ Forward-looking statements Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2021 and Form 20-F, which both were filed with the SEC in February 2022 in continuation of the publication of this Annual Report 2021, this presentation, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as 'believe', 'expect, 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to: Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto, Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures, Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result of interruptions or delays affecting supply chains on which Novo Nordisk relies, product recalls, unexpected contract breaches or terminations, government- mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology including the risk of cybersecurity breeches, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, failure to maintain a culture of compliance, epidemics, pandemics or other public health crises, and factors related to the foregoing matters and other factors not specifically identified herein. For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in this Annual Report 2021, reference is made to the overview of risk factors in 'Risk management' of this Annual Report 2021. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this Annual Report 2021, whether as a result of new information, future events, or otherwise. Important drug information VictozaⓇ and OzempicⓇ are approved for the management of type 2 diabetes only SaxendaⓇ and WegovyⓇ are approved in the USA and the EU for the treatment of obesity only CMD22 CAPITAL MARKETS DAY#3Commercial execution 3 Commercial execution and innovation Diabetes care Strategic aspirations 2025 Purpose and sustainability (ESG) Progress towards zero environmental impact Being respected for adding value to society Being recognised as a sustainable employer Strengthen Diabetes leadership - aim at global value market share of more than 1/3 Strengthen Obesity leadership and double current sales¹ Secure a sustained growth outlook for Rare disease Financials therapeutic focus Innovation and OIIIIII • Further raise the innovation-bar for diabetes treatment Develop a leading portfolio of superior treatment solutions for obesity Strengthen and progress the Rare disease pipeline Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD Deliver solid sales and operating profit growth Deliver 6-10% sales growth in IO • Transform 70% of sales in the US² Drive operational efficiencies across the value chain to enable investments in future growth assets ⚫ Deliver free cash flow to enable attractive capital allocation to shareholders 1 Based on reported sales in 2019, 2 From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease. Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth. CMD22 CAPITAL MARKETS DAY Novo NordiskⓇ#44 Commercial execution and innovation Diabetes care Diabetes prevalence increases, yet only ~50% of people with diabetes are diagnosed and even fewer reach HbA1c target In 2045, 784 million adults are expected to live with diabetes 1 in 2 adults go undiagnosed and more treated patients should reach their HbA1c target Million 1,000 1 in 10 have diabetes 800 643 600 537 400 200 1 in 8 have diabetes 537m 784 35m Novo NordiskⓇ 2021 2030 2045 Prevalence Diagnosed Treated Reach target Treated for complications EMEA Region China Rest of World North America Prevalence Novo Nordisk products Note: Region China is the Western Pacific number, i.e. also includes Australia which in NN's regions belongs to Rest of World Source: Diabetes prevalence and diagnosed are based on Diabetes Atlas 10th edition, 2021; Treated is based on IQVIA patient data; real-world studies indicate between 30-55% of patients reach HbA₁ target <7% .e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/ CMD22 CAPITAL MARKETS DAY#55 Commercial execution and innovation Diabetes care Better outcomes and broader reach can be accomplished through continued innovation, supported by digital solutions Novo Nordisk's product portfolio follows the patient treatment journey OZEMPIC TRESIBA Xultophy Portfolio and pipeline Digital health solutions RYBELSUS® semaglutide tablets semaglutide injection insulin degludec [rDNA origin] injection High dose oral semaglutide Uncontrolled on current OAD Semaglutide 2.0 mg Icodec IcoSema Needing first injectable Needing first basal insulin Needing more than basal insulin Novo PenⓇ6 / Novo Pen Echo® Plus are smart insulin pens and launched in 8 countries CGM: Continuous glucose monitoring; Grey boxes in the portfolio and pipeline references phase 2 or phase 3 assets. Abbott 0 Medtronic 000 600 RYZODEG® Fiasp fast-acting insulin aspart Needing added meal- time insulin control mySugr Roche Partnered with global CGM players glooko Dexcom® CMD22 CAPITAL MARKETS DAY Novo NordiskⓇ#66 Commercial execution and innovation Diabetes care GLP-1 and SGLT-2i have been driving the value growth of the global diabetes care market Estimated global number of patients 192 million CAGR: +4% Estimated global diabetes value market $ CAGR: +5% 218 million USD 47 billion USD 55 billion 2018 Insulin 2021 2018 GLP-1 SGLT-2i DPP-4i 2021 Traditional OADs • Novo Nordisk® Diabetes market dynamics Continued strong growth momentum in GLP-1 and SGLT-2i segments, but from a larger base DPP-4i segment to have first patent expiries on key products within the coming two years Flat insulin volume growth and continued insulin pricing pressure Note: GLP-1+basal insulin combination sales are included in insulin; Traditional OADS include metformin, SU and TZDS. CAGR: Compound annual growth rates. OAD: Oral anti-diabetes Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP-1, SGLT-2i and DPP-4i and IQVIA data for traditional OADs as of December 2018 and 2021 CMD22 CAPITAL MARKETS DAY#77 Commercial execution and innovation Diabetes care Use of GLP-1 treatments has increased globally, yet only ~6 million people treated ~6 million people, 3% of diabetes prescriptions, use a GLP-1 with large differences across markets Million people 7 6 5 4 OZEMPİC semaglutide injection RYBELSUSⓇ semaglutide tablets Global: 3% 8% 3 2 1% 1% 3% 1 0 2017 2021 EMEA Region China Rest of World North America GLP-1 share of diabetes prescription EMEA: Europe, Middle East and Africa; Region China covers Mainland China, Taiwan and Hong Kong Source: IQVIA MAT, December 2021 Novo NordiskⓇ CMD22 CAPITAL MARKETS DAY#88 Commercial execution and innovation Diabetes care Novo Nordisk progresses towards strategic aspiration of reaching more than 1/3 of the diabetes value market Diabetes care sales Progress made towards Strategic Aspiration DKK billion Value market share 120 6% 4% 4% 8% 13% 80% 100 80 00 60 60 40 40 20 20 0 2017 Injectable GLP-1 Growth at CER 2018 2019 2020 2021 Oral GLP-1 Insulin Other Diabetes care CER: Constant exchange rates; NN: Novo Nordisk; MS: Market share Source: Reported sales per year and sales growth at CER; IQVIA MAT, December 2021 (Spot rate) 60% 49.1% 40% 42.3% 27.5% 20% Novo NordiskⓇ 53.1% 44.0% 30.3% 0% Dec 2017 Dec 2021 NN diabetes MS NN GLP-1 MS NN insulin MS CMD22 CAPITAL MARKETS DAY#9Diabetes care Diabetes care sales in IO driven by both GLP-1 and insulin 9 Commercial execution and innovation DKK billion 60 60 50 40 40 30 20 20 10 10 Diabetes care sales and growth in IO 5% 6% 10% 11% 14% 0 2017 Insulin Novo NordiskⓇ Must-win battles for IO Drive insulin sales and patient base TRESIBA insulin degludec [rDNA origin] injection 37.7% NN basal value market share RYZODEG 70% insulin degludec and 30% insulin aspart [rDNA origin] injection 69.3% NN mix value market share Drive GLP-1 market growth OZEMPİC semaglutide injection RYBELSUS semaglutide tablets 27 launch markets 59.4% 2018 2019 2020 2021 Injectable GLP-1 Oral GLP-1 Other Diabetes care NN GLP-1 value market share Growth at CER IO: International Operations; CER: Constant exchange rates; NN: Novo Nordisk Source: Reported sales and growth at CER; IQVIA MAT value December 2021 CMD22 CAPITAL MARKETS DAY#1010 Commercial execution and innovation Diabetes care Region China remains a key strategic opportunity Region China is a large market with ~140 million people living with diabetes . Outcome of VBP insulin in China Price cuts ~40-50% as a result of VBP Keeps -50% of own brand volume in scope 22% 23% • Resource re-allocation towards growth products 78% 77% IO sales IO patients Region China Rest of IO TRESIBA insulin degludec [rDNA origin] injection NovoMix® (biphasic insulin aspart) human insulin MixtardⓇ30 Levemir® (insulin detemir) biphasic insulin Novo Rapid (insulin aspart) RYZODEG 70% insulin degludec and 30% insulin aspart [rDNA origin] injection Xultophy insulin degludec/liraglutide [rDNA origin] injection OZEMPİC semaglutide injection Note: IQVIA value in China only covers -60% of the market Region China includes Mainland China, Taiwan and Hong Kong; VBP: Volume-based procurement; OAD: Oral anti-diabetes; IO: International Operations Source: IQVIA, MAT value December 2021 Opportunities and strategic priorities 跟 Large growing diabetes market Market of 25 bDKK mainly consisting of OAD and insulin Diabetes market growth of ~7% DO • Bring innovation faster to market Diabetes: RybelsusⓇ and ONWARDS programme for Icodec Rare disease: Across portfolio Treat more patients Expand patient base across new insulins and GLP-1s Novo NordiskⓇ CMD22 CAPITAL MARKETS DAY#1111 Commercial execution and innovation Diabetes care Despite uptake of GLP-1s, few patients are treated in International Operations GLP-1 increases as part of the diabetes value market 5% 14% OzempicⓇ sales in IO in million DKK 8,855 Novo NordiskⓇ A fraction of diabetes prescriptions are GLP-1s (% of total diabetes market) 32% 19% 14% 8% 10% 6% 39 2% 3% 1% 1% 2021 2018 2021 Total NAO Total IO EMEA ROW Region China GLP-1 value share GLP-1 volume share 2016 Insulin GLP-1 OADS ROW: Rest of world; EMEA: Europe, Middle East and Africa; Region China includes Mainland China, Taiwan and Hong Kong; OAD: Oral anti-diabetes medicine; IO: International Operations; NAO: North America Operations Source: IQVIA December 2021 CMD22 CAPITAL MARKETS DAY#1212 Commercial execution and innovation Diabetes care Novo NordiskⓇ RybelsusⓇ has only just started to be commercially available in IO with Japan being the biggest opportunity RybelsusⓇ is Novo Nordisk's entry into 55% of the diabetes market IO diabetes market is DKK ~200 billion Strong start for RybelsusⓇ in Japan's DKK 20 billion MOAD market after 14-day prescription restriction was lifted TRX ('000) 45% injectable 55% oral 100 80 60 60 60 25% 24% 40 40 46% 20 75% 20 OAD Traditional OAD MOAD 30% 0 1 5 9 Restriction lifted¹ 17 MOAD Months after launch Japan Next 12 countries -RybelsusⓇ All other countries canagliflozin -ipragliflozin -empagliflozin ―dapagliflozin ¹Time for the 14-day prescription restriction lifted for the respective products OAD: Oral anti-diabetes; MOAD: modern oral anti-diabetes market; IO: International Operations Source: IQVIA value spot rate December 2021, IQVIA LRX December 2021 CMD22 CAPITAL MARKETS DAY#1313 Commercial execution and innovation Diabetes care Novo NordiskⓇ OzempicⓇ and Rybelsus® are driving the diabetes care sales growth in North America Operations Diabetes care sales and growth in North America Operations North America Operations has been on a journey of: DKK billion 60 6% 50 40 40 30 20 20 10 2% 3% 5% 12% 0 2017 2018 2019 2020 2021 Injectable GLP-1 Oral GLP-1 Insulin Other Diabetes care Growth at CER CER: Constant exchange rates Note: Blockbuster products are products reaching USD 1 billion in sales Transforming ~70% of US sales by 2022 Status: 60% Notably increasing the number of patients treated Progress: Treating ~30% more patients since 2017 Bringing two new blockbuster products to the market Progress: Ozempic® is a 3x blockbuster and RybelsusⓇ is approaching blockbuster status just two years after launch CMD22 CAPITAL MARKETS DAY#1414 Commercial execution and innovation Diabetes care Novo NordiskⓇ OzempicⓇ is driving growth in the GLP-1 class, which is still a small proportion of the US diabetes market 32% of diabetes market value is GLP-1 ~8% of diabetes NBRX share prescriptions are GLP-1 80% US GLP-1 NBRx market share ~30% GLP-1 volume market growth Oral GLP-1 0.5% 8% Inj. GLP-1 60% SGLT-2i 8% DPP-4i 7% Insulin 29% 40% OAD 48% 20% 63.1% 45.2% 35.4% 11.9% 6.0% 0% Diabetes volume1 market share by segment Jan 2021 Feb 2022 - OzempicⓇ RybelsusⓇ dulaglutide - NN GLP-1 VictozaⓇ 1 Diabetes volume measured in prescriptions NBRX: New to brand prescription; OAD: oral anti-diabetes meditation Source: IQVIA, left hand side chart is IMS World data from Dec'21 and right hand sight chart is IQVIA data from the week ending 4 February 2022 CMD22 CAPITAL MARKETS DAY#1515 Commercial execution and innovation Diabetes care Novo NordiskⓇ OzempicⓇ launch has helped drive the changing treatment. paradigm in the US 15% intensifies with non-generic treatment within 18 months of starting metformin OzempicⓇ launch increases the use of GLP-1 as intensification after metformin More than 60% of patients choose Novo Nordisk GLP-1 products 39% 15% 25% 17% 11% 35% 15%2 People starting on metformin¹ Treatment change within 18 months Before OzempicⓇ launch After Ozempic launch GLP-1 choice Ⓡ Ⓡ Non-generic Generic Metformin Insulin GLP-1 SGLT-2i DPP-4i Ozempic Rybelsus VictozaⓇ OAD: oral anti-diabetes medication; Note: All numbers are from the North America Operations. The analysis is made by comparing patients starting metformin in Q1 2017 with patients starting metformin in Q4 2019 and has 300+ unique regimens grouped based on subclass hierarchy (GLP-1 reflects GLP-1 only, as well as regimens including any combination of subclasses), regimens hierarchy: insulin, GLP-1, SGLT2, DPP4, generic. Considering patients that started on Metformin (844K patients) Source: IQVIA, MAT Dec'21 Other CMD22 CAPITAL MARKETS DAY#1616 Commercial execution and innovation Diabetes care RybelsusⓇ is well-positioned in a competitive OAD market US OAD market is ~100 bDKK Positioning RybelsusⓇ earlier in the treatment cascade Novo NordiskⓇ Rybelsus® is capturing new patients in the modern OAD market -3% MOAD volume market growth 2% >90% of people starting on RybelsusⓇ are new to the GLP-1 class TRX share 35% Source of business for new to GLP-1 30% 39% 25% 76% 11% 13% 20% 49% 15% 54% 19% 8% 10% 11% 5% 13% 1% Patients 6% Value Metformin/Naïve DPP-4i 0% Oct SGLT-2i Other OADs 2019 Oral GLP-1 SGLT-2i DPP-4i Other OAD Insulin TRX: Total prescriptions; OAD: oral anti-diabetes medication; MOAD: Modern oral antidiabetes medication Source: Internal sales benchmark, CER; IQVIA, Xponent; IQVIA Nov'21-Feb'22 vs Aug'21-Nov'21 MOAD market growth 4% Feb 2022 ―sitagliptin empagliflozin Rybelsus CMD22 CAPITAL MARKETS DAY#1717 Commercial execution and innovation Diabetes care Raising the innovation-bar for diabetes treatment Further raise the innovation bar for diabetes treatment Unmet need within diabetes remain large Moving towards patient outcomes beyond blood glucose lowering Developing differentiated next-generation injectable and oral GLP-1-based offerings Digital health to provide improved patient support and to achieve clinical trial results in the real world Novo NordiskⓇ Development pipeline 2022 2023 2024 2025 Semaglutide 2.0 mg, QW GLP-1 US regulatory feedback pending CagriSema, FDC QW incretin treatment Phase 2 Semaglutide+GIP, FDC QW incretin treatment Phase 2 Injectable incretins Semaglutide 1.0 mg in PAD Phase 3 Semaglutide 1.0 mg in diabetic retinopathy Semaglutide 1.0 mg in chronic kidney disease Oral semaglutide 25 mg and 50 mg Phase 3 Phase 3 Phase 3 Oral incretins SOUL, oral semaglutide 14 mg CVOT Icodec, QW basal insulin Phase 3 (indicative, event-driven) Phase 3 IcoSema, QW FDC basal insulin and GLP-1 Phase 3 Insulin projects Ideal Pump Insulin (type 1 diabetes) Phase 1 Glucose-sensitive insulin Phase 1 Other DNA Immunotherapy (type 1 diabetes) Phase 1 GIP: Gastric inhibitory polypeptide; FDC: Fixed-Dose Combination; QW: Once weekly; PAD: Peripheral arterial disease; CVOT: Cardiovascular outcome trial; cagri: Cagrilintide; sema: semaglutide; Ico: Icodec#1818 Commercial execution and innovation Diabetes care Novo Nordisk® Sema 2.0 mg showed superior HbA1c reduction and additional weight reduction with similar number of GI AEs vs sema 1.0 mg 0.0 Semaglutide 2.0 mg showed a statistically significant HbA1c reduction of 2.2% in SUSTAIN FORTE Additional efficacy and safety parameters Semaglutide 2.0 mg Change from baseline (%-point) -0.5 -1.0 -1.5 -2.0 -2.5 Semaglutide 1.0 mg (n=481) (n=480) Additional efficacy Body weight (kg) -6.0 -6.9* % of participants achieving HbA1c 57.5 67.6 <7.0% % of participants achieving HbA1c 38.5 51.7 <6.5% 1.9% Safety 2.2%* Disc. due to AEs 4.6% 4.4% Nausea 14.6% 14.4% Diarrhoea 8.8% 9.4% Vomiting 6.7% 7.7% 0 12 16 20 Time since randomisation (weeks) 28 40 EOT -Semaglutide 1.0 mg -Semaglutide 2.0 mg Note: * Statistically significant; shown data is based on the trial product estimand. GI: Gastrointestinal; AE: Adverse events; Sema: semaglutide; Disc: discontinuation; EOT: End of trial CMD22 CAPITAL MARKETS DAY#1919 Commercial execution and innovation Diabetes care Insulin icodec, a basal insulin intended for once-weekly treatment, may reduce the disease burden for patients Bringing the strongest value proposition to market Insulin icodec phase 3 programme expected to complete during 2022 TIR: Time-in-range ONWARDS 1 970 people insulin-naïve, 78-week, vs insulin glargine U100 Reduction of disease burden with once-weekly treatment 520 people on basal, 26- ONWARDS 2 Tested for superior HbA₁ and TiR vs glargine and standard-of-care and week, vs insulin degludec 580 people insulin-naïve, 26-week, ONWARDS 3 similar safety profile of TresibaⓇ vs insulin degludec ONWARDS 4 App-based offering and connected smart pen to optimise titration and support compliance and data collection ONWARDS 5 ONWARDS 6 Reduced environmental footprint 580 people on both basal and bolus, 26-week, vs insulin degludec 1,100 people, insulin-naïve using app-based dosing recommendations, 52-week 580 people, type 1 diabetes using bolus insulin, 52-week, vs insulin degludec 2022 Novo NordiskⓇ CMD22 CAPITAL MARKETS DAY#2020 20 Commercial execution and innovation Diabetes care Novo Nordisk® Exploring semaglutide to address the unmet needs of people with diabetes, beyond lowering blood glucose O FOCUS Diabetic retinopathy outcomes trial Semaglutide 1.0 mg, injectable + standard of care • ~1,500 patients with T2D for 10 or more years Primary endpoint: Presence of ≥3 steps ETDRS patient level progression Estimated completion in 2027 SOUL Cardiovascular outcomes trial Semaglutide 14 mg, oral • • ~9,600 patients with T2D, established CVD or CKD Primary endpoint: Time to first major adverse cardiovascular event¹ Estimated completion in 2024 ✓ STRIDE Peripheral arterial disease Semaglutide 1.0 mg, injectable ~800 patients with type 2 diabetes and PAD Primary endpoint: Change in maximum walking distance • Estimated completion in 2024 GO FLOW Chronic kidney disease outcomes trial Semaglutide 1.0 mg, injectable ~3,500 patients with T2D, moderate to severe CKD Primary endpoint: Time to first occurrence of a composite primary outcome event² • Estimated completion in 2024 1 Major adverse cardiovascular event defined as CV death, non-fatal stroke or non-fatal myocardial infarction; 2Defnined as persistent eGFR decline of ≥50% from trial start, reaching end stage renal disease, death from kidney disease or death from cardiovascular disease T2D: Type 2 diabetes; CVD: Cardiovascular disease; PAD: Peripheral arteries disease; ETDRS: Early treatment diabetic retinopathy study; CKD: Chronic kidney disease CMD22 CAPITAL MARKETS DAY#2121 Commercial execution and innovation Diabetes care Fixed dose combination with semaglutide and cagrilintide currently investigated in phase 2 with completion in 2022 90 participants with T2D HbA1c 7.5-10.5% Phase 2 trial design for CagriSema Randomisation (1:1:1) Cagrilintide OW + semaglutide OW • Met +/- SGLT-2i •BMI >27 kg/m2 Cagrilintide OW + placebo OW Semaglutide OW + placebo OW --+- _ Dose escalation 16 weeks Treatment maintenance FU 5 16 weeks weeks Role of amylin analogues in diabetes treatment Amylin is a naturally occurring hormone. When administered it lowers blood glucose in four ways • Slow gastric emptying, preventing blood sugar rising too fast Lowers the glucose production in the liver Increases satiety • Lowering of glucagon in connection with meals Novo NordiskⓇ Trial objective: Compare the effect on glycaemic control and body weight of cagrilintide in combination with semaglutide vs semaglutide in patients with type 2 diabetes Primary endpoint: Change in HbA1c (%-point) Next steps: 37-week trial was initiated in Q3 2021 Next steps Ongoing phase 2 trials for CagriSema and semaglutide in combination with GIP is expected to complete during second half of 2022 T2D: Type 2 diabetes; FU: Follow-up; Q: quarter; OW: Once-weekly; Cagrisema: cagrilintide in combination with semaglutide CMD22 CAPITAL MARKETS DAY#22Commercial execution / Innovation and therapeutic focus Closing remarks Number of people with diabetes continues to increase GLP-1 treatments are driving the growth of the diabetes care market, yet only 3% of prescriptions Insulin icodec has the potential to reduce the disease burden and improve outcome Novo Nordisk is progressing towards achieving more than a 1/3 of the diabetes value market novo nordisk SIMONE LENSBØLE Simone lives with type 2 diabetes Denmark